10% Owner Daniel Schneeberger Buys Additional $711K in Rallybio Stock

summarizeSummary

Daniel Schneeberger, a 10% owner of Rallybio Corp, made additional open market purchases totaling over $711,000, increasing his stake in the company following a recent merger termination.

check_boxKey Events

• Significant Insider Purchase

  Daniel Schneeberger, a 10% owner, acquired 50,800 shares of Rallybio common stock in open market transactions totaling $711,055. These purchases occurred between May 11 and May 12, 2026, at prices ranging from $13.83 to $14.00 per share.

• Continued Accumulation

  This filing marks a continuation of significant buying by Schneeberger, following a previous Form 4 on May 7, 2026, which reported over $2.18 million in purchases. His total open market buys in the past week now approach $2.9 million.

• Post-Merger Termination Context

  These insider purchases occur shortly after Rallybio Corp announced the termination of its reverse merger agreement with Candid Therapeutics on May 4, 2026. The termination included a $50 million fee, which significantly bolstered Rallybio's cash reserves and extended its operational runway.

auto_awesomeAnalysis

This continued substantial open market buying by a 10% owner, Daniel Schneeberger, signals strong conviction in Rallybio's prospects. These purchases follow the recent termination of a reverse merger agreement, which resulted in a $50 million termination fee, significantly boosting the company's cash reserves. The repeated insider investment suggests a positive outlook on the company's standalone strategy and financial health.